Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
Revenue
Neurocrine Biosciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Revenue
$1.9B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
92%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Neurocrine Biosciences Inc
Revenue Breakdown
Breakdown by Geography
Neurocrine Biosciences Inc
Breakdown by Segments
Neurocrine Biosciences Inc
Total Revenue:
1.9B
USD
|
Net Product Sales:
1.9B
USD
|
Collaboration Revenue:
26.5m
USD
|
See Also
What is Neurocrine Biosciences Inc's Revenue?
Revenue
1.9B
USD
Based on the financial report for Dec 31, 2023, Neurocrine Biosciences Inc's Revenue amounts to 1.9B USD.
What is Neurocrine Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
92%
Over the last year, the Revenue growth was 27%. The average annual Revenue growth rates for Neurocrine Biosciences Inc have been 22% over the past three years , 33% over the past five years , and 92% over the past ten years .